Skip to Content

SHARE

Clinical Trials Details

Relapsed, Indolent or Aggressive Non-Hodgkins Lymphoma (NHL)

BAY 80-6946, PI3K inhibitor in patients with relapsed, indolent or aggressive Non-Hodgkin's Lymphoma (NHL)

Objective
  • Follicular Lymphoma grade 1,2,3a
  • Small lymphocytic lymphoma
  • Lymphoplasmacytoid lymphoma/Waldenstrom Macroglobulinemia
  • Marginal zone lymphoma

Relapsed or refractory after equal or greater than 2 prior lines of therapy.  Patients must have received Rituxan.

IRB Protocol Number
BAY 80-6946
Principal Investigator(s)
Brock Whittenberger, MD
Sponsor(s)
Bayer Healthcare
Contact
Linda Allen, RN OCN at 406-435-7481
or lallen@billingsclinic.org

Location

  • Billings Clinic Hospital Fountain Courtyard - South of the Hospital Cafeteria
    2750 9th Ave North
    Billings, MT 59101